CMX521

CMX521
Legal status
Legal status	US: Investigational drug;
Identifiers
	IUPAC name 4-amino-7--2-methylpyrrolopyrimidine-5-carboxamide;
CAS Number	2077178-99-3 ;
PubChem CID	126520436;
UNII	76US2C2X3F;
Chemical and physical data
Formula	C13H17N5O5
Molar mass	323.309 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=NC(=C2C(=CN(C2=N1)3(((O3)CO)O)O)C(=O)N)N;
	InChI InChI=1S/C13H17N5O5/c1-4-16-10(14)7-5(11(15)22)2-18(12(7)17-4)13-9(21)8(20)6(3-19)23-13/h2,6,8-9,13,19-21H,3H2,1H3,(H2,15,22)(H2,14,16,17)/t6-,8-,9-,13-/m1/s1; Key:PMQFVTNOZQVIOK-HTVVRFAVSA-N;

CMX521 is an antiviral drug discovered by Chimerix, which was developed for the treatment of norovirus, though it also shows efficacy against related viral diarrheas such as rotovirus and some sapoviruses, astroviruses and adenoviruses. It is a nucleoside analogue which acts as an inhibitor of viral RNA-dependant RNA polymerase.^[1]^[2]^[3]

References

^ Bassetto M, Van Dycke J, Neyts J, Brancale A, Rocha-Pereira J (February 2019). "Targeting the Viral Polymerase of Diarrhea-Causing Viruses as a Strategy to Develop a Single Broad-Spectrum Antiviral Therapy". Viruses. 11 (2): 173. doi:10.3390/v11020173. PMC 6409847. PMID 30791582.
^ Netzler NE, Enosi Tuipulotu D, White PA (May 2019). "Norovirus antivirals: Where are we now?". Medicinal Research Reviews. 39 (3): 860–886. doi:10.1002/med.21545. PMC 7168425. PMID 30584800.
^ Ebenezer O, Jordaan MA, Damoyi N, Shapi M (December 2020). "Discovery of Potential Inhibitors for RNA-Dependent RNA Polymerase of Norovirus: Virtual Screening, and Molecular Dynamics". International Journal of Molecular Sciences. 22 (1): 171. doi:10.3390/ijms22010171. PMC 7795727. PMID 33375298.

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.

Zdroj:https://en.wikipedia.org?pojem=CMX521
Text je dostupný za podmienok Creative Commons Attribution/Share-Alike License 3.0 Unported; prípadne za ďalších podmienok. Podrobnejšie informácie nájdete na stránke Podmienky použitia.

[1] Bassetto M, Van Dycke J, Neyts J, Brancale A, Rocha-Pereira J (February 2019). "Targeting the Viral Polymerase of Diarrhea-Causing Viruses as a Strategy to Develop a Single Broad-Spectrum Antiviral Therapy". Viruses. 11 (2): 173. doi:10.3390/v11020173. PMC 6409847. PMID 30791582.

[2] Netzler NE, Enosi Tuipulotu D, White PA (May 2019). "Norovirus antivirals: Where are we now?". Medicinal Research Reviews. 39 (3): 860–886. doi:10.1002/med.21545. PMC 7168425. PMID 30584800.

[pmid33375298-3] Ebenezer O, Jordaan MA, Damoyi N, Shapi M (December 2020). "Discovery of Potential Inhibitors for RNA-Dependent RNA Polymerase of Norovirus: Virtual Screening, and Molecular Dynamics". International Journal of Molecular Sciences. 22 (1): 171. doi:10.3390/ijms22010171. PMC 7795727. PMID 33375298.

[1]

[2]

[3]

Legal status

Legal status	US: Investigational drug
Identifiers
IUPAC name 4-amino-7--2-methylpyrrolopyrimidine-5-carboxamide
CAS Number	2077178-99-3^Y
PubChem CID	126520436
UNII	76US2C2X3F
Chemical and physical data
Formula	C₁₃H₁₇N₅O₅
Molar mass	323.309 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CC1=NC(=C2C(=CN(C2=N1)3(((O3)CO)O)O)C(=O)N)N
InChI InChI=1S/C13H17N5O5/c1-4-16-10(14)7-5(11(15)22)2-18(12(7)17-4)13-9(21)8(20)6(3-19)23-13/h2,6,8-9,13,19-21H,3H2,1H3,(H2,15,22)(H2,14,16,17)/t6-,8-,9-,13-/m1/s1 Key:PMQFVTNOZQVIOK-HTVVRFAVSA-N

See also

References